AVCE Avicena Group Inc featured news, full reports, and detailed charts
Avicena Group Inc (AVCE/AVCE.PK) Wrap Up:
Avicena Group, Inc., a biotechnology company, develops central nervous system therapeutics for neurodegenerative diseases. The company's technologies have applications in both pharmaceuticals and dermaceuticals. Its pharmaceutical program centers on rare neurological disorders (orphan diseases). The company plans to initiate a Phase III trial in Huntington's disease and a confirmatory Phase III trial in amyotrophic lateral sclerosis to accompany the ongoing NIH Phase III trial in Parkinson's disease. The company focuses on developing orphan drug products for neurological diseases, such as Amyotrophic Lateral Sclerosis (ALS), Huntington’s, and Creatine Transporter Defect; as well as cosmeceut...Avicena Group Inc (AVCE:OTC)
|
Market Cap
253.7K
|
Total Revenue
403.9K
|
|
|
EBITDA
8.9M
|
DILUTED EPS TTM
-0.27
|
|
|
P/E
--
|
P/S
0.6x
|
|
|
Return On Asset
-270.43
|
Return On Equity
145.18
|
|
| K = Thousands M = Millions B = Billions | ||
AVCE Top Compensated Officers
Executives, Board Directors
Key developments for Avicena Group Inc (AVCE)
Avicena Group Inc. announced that on November 21, 2008, pursuant to Section 5B of the company’s Series A Preferred Stock Certificate of Designations, a majority of the holders of the company’s Series A Preferred Stock elected Ted Gomoll to the company’s Board of Directors as the Series A Preferred Director, effective immediately. Mr. Gomoll, a Chartered Financial Analyst, is a principal with Mill Valley Partners, an investment advisory firm. Pursuant to a letter agreement dated as of October 18, 2008 with the company, Mr. Gomoll currently serves as a financial, strategic and operational advisor to the company, in conjunction with Rick Stewart, also a member of the Registrant’s Board of Directors, providing counsel to the company’s Board of Directors on certain transactions of the company, including any recapitalization, restructuring, sale of assets, stock or a change of control of the company.
Avicena Group Inc. announced that on November 28, 2008, Ryan Kiss, a member of the Board of Directors, notified his fellow directors of his resignation from the Board, effective immediately.
On 09/26/2008, Avicena Group Inc announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
AVCE Competitors
| Company | Last | Change |
| Aeolus Pharmaceuticals Inc | $0.30 USD | 0.00 |
| Sanofi - Aventis | €50.37 EUR | +0.07 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | AVCE | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.6x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
AVCE |
||
AVCE transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||